Corrections to: "Effi cacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non- nferiority ENCORE1 study" [Lancet Infect Dis (2015)] DOI: 10.1016/S1473-3099(15)70060-5;Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

The Lancet Infectious Diseases

Volumn 15, Issue 7, 2015, Pages 793-802

  Amin, Janaki ^a   Becker, Stephen ^a   Belloso, Waldo ^a   Boffito, Marta ^a   Cooper, David ^a   Crabtree Ramirez, Brenda ^a   Duncombe, Chris ^a   Foulkes, Sharne ^a   Hill, Andrew ^a   Jessen, Heiko ^a   Kumar, Suresh ^a   Lee, Man Po ^a   Nwizu, Chidi ^a   Read, Tim ^a   Rooney, Jim ^a   Schaffer, Kim ^a   Shahar, Eduardo ^a   Winston, Alan ^a   Wolff, Marcelo ^a   Young, Barnaby ^a   Abela, Cecilia ^a   Avihingsanon, Anchalee ^a   Boyd, Mark ^a   Carey, Dianne ^a   Clarke, Amanda ^a   Courtney Vega, Kymme ^a   Delfino, Marina ^a   Donaldson, Anna ^a   Emery, Sean ^a   Espinosa, Natalie ^a   Johannesen, Tanya ^a   Lin, Enmoore ^a   Losso, Marcelo ^a   Moricz, Alejandra ^a   Pett, Sarah ^a   Phanupak, Praphan ^a   Puls, Rebekah ^a   Pussadee, Kanitta ^a   Sutheerasak, Parinya ^a   Tomlins, Louise ^a   Ubolyam, Sasiwimol ^a   bin Raja Azwa, Raja Iskandar Shah ^a   Bissio, Emiliano ^a   Calanni, Liliana ^a   Chetchotisakd, Ploenchan ^a   Doong, Nicholas ^a   Elliott, Julian ^a   Gazzard, Brian ^a   Kelly, Mark ^a   Laplume, Hector ^a   del Carmen Luna, Norma ^a   Lupo, Sergio ^a   Messina, Oscar Garcia ^a   Mohapi, Lerato ^a   Moore, Richard ^a   Nolan, David ^a   Orrell, Catherine ^a   Perez, Carlos ^a   Phanuphak, Praphan ^a   Rockstroh, Jürgen ^a   Rowling, Diane ^a   Supparatpinyo, Khuanchai ^a   Smith, Don ^a   Villanueva, Jaime Andrade ^a   Vlahakis, Emanuel ^a   Kelleher, Tony ^a   Cunningham, Philip ^a   Merlin, Kate ^a   Yeung, Julie ^a   Shaik, Ansari ^a   Fsadni, Bertha ^a   Carrera, Alex ^a   Lograsso, Melanie ^a   Gulick, Roy ^a   Dunn, David ^a   Dolan, Matthew ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; PLACEBO; TENOFOVIR; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTIC SHOCK; STEVENS JOHNSON SYNDROME; SUICIDE; SUICIDE ATTEMPT; VIRUS LOAD; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; HIV INFECTIONS; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES;

ADENINE; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84937512973     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00004-3     Document Type: Erratum

References (30)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, (accessed Nov 15, 2014). http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
2. Guidelines. Version 7.02 European AIDS Clinical Society, (accessed Sept 28, 2014). http://eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf.
3. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach June, 2013, WHO, World Health Organization, Geneva, (accessed Sept 19, 2014). http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1.
4. Center for Drug Evaluation and Research Medical Review Application number 20-972 US Food and Drug Administration, (accessed Sept 10, 2014). http://accessdata.fda.gov/drugsatfda_docs/nda/98/20972clinical_review.pdf.
5. Haas D, Hicks C, Seekins D, et al. A phase 2, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (DMP 266) in combination with open-label zidovudine and lamivudine at 24 weeks (DMP 005). Fifth Conference on Retroviruses and Opportunistic Infections; Chicago, IL, USA; Feb 1-5, 1998. Abstract 698.
6. Political declaration on HIV and AIDS: intensify our efforts to eliminate HIV and AIDS, 65/277 United Nations General Assembly, (accessed Sept 1, 2014). http://un.org/en/ga/search/view_doc.asp?symbol=A/RES/65/27.
7. Global update on the health sector response to HIV. July, 2014. Executive Summary. Geneva: World Health Organization WHO, (accessed Oct 2, 2014). http://apps.who.int/iris/bitstream/10665/128196/1/WHO_HIV_2014.15_eng.pdf?ua=1.
8. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014, 383:1474-1482. ENCORE1 Study Group.
9. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. African Region WHO, (accessed Aug 26, 2014). http://who.int/hiv/pub/guidelines/clinicalstaging.pdf.
10. Revised classification system for HIV infection and expanded surveillance sase definition for AIDS among adolescents and adults Centers for Disease Control and Prevention, (accessed Aug 28, 2014). http://cdc.gov/mmwr/preview/mmwrhtml/00018871.htm.
11. Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective WHO, (accessed Sept 1, 2014). http://apps.who.int/iris/bitstream/10665/70920/1/9789241503792_eng.pdf?ua=1.
12. Ware J, Kosinski M, Keller SD A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233.
13. Henry J, Crawford J The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol 2005, 44:227-239.
14. Chesney M, Ickovics J, Chambers D, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12:255-266.
15. HIV drug resistance database Stanford University, (accessed Aug 28, 2014). http://hivdb.stanford.edu.
16. Stocrin Product Information Merck Sharp & Dohme (Australia), (accessed Sept 3, 2014). http://secure.healthlinks.net.au/content/msd/pi.cfm?product=mkpstocr.
17. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010, 51:855-864.
18. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378:229-237.
19. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806.
20. Pilon AA, Lum JJ, Sanchez-Dardon J, Phenix BN, Douglas R, Bradley AD Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother 2002, 46:2687-2691.
21. Lanzafame M, Bonora S, Lattuada E, Vento S Efavirenz dose reduction in HIV-infected patients. HIV Med 2012, 13:252-253.
22. Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009, 151:149-156.
23. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010, 24:1923-1928.
24. Frentz D, Boucher CA, van de Vijver DA Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012, 14:17-27.
25. Parikh UM, Kiepiela P, Ganesh S, et al. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One 2013, 8:e59787.
26. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008, 197:867-870.
27. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305:1327-1335.
28. Lee GQ, Bangsberg DR, Muzoora C, et al. Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses 2014, 30:896-906.
29. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March, 2011). The Cochrane Collaboration, 2011. (accessed Jan 10, 2015). http://handbook.cochrane.org.
30. Leutkemeyer AF, Rosenkranz SL, Lu D, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampicin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE study. Clin Infect Dis 2013, 57:586-593.